Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q15835
UPID:
GRK1_HUMAN
Alternative names:
G protein-coupled receptor kinase 1
Alternative UPACC:
Q15835; Q53X14
Background:
Rhodopsin kinase GRK1, also known as G protein-coupled receptor kinase 1, plays a pivotal role in the human retina. It is crucial for the signal turnoff by phosphorylating rhodopsin, the receptor initiating the phototransduction cascade. This process is vital for scotopic vision, allowing rapid adaptation to changes in illumination. GRK1's function is essential in maintaining the outer nuclear layer of the retina.
Therapeutic significance:
GRK1 is directly linked to Night blindness, congenital stationary, Oguchi type 2, a retinal disorder characterized by impaired night vision. Understanding the role of Rhodopsin kinase GRK1 could open doors to potential therapeutic strategies for this and related visual impairments.